

RKSC PUBLICATION LIST

Publications:

1. Goldfarb DS, and Hirsch J. Hypothesis: Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones. *Medical Hypotheses*. Accepted 4 Sept 2015. PMID: PMC4551564.
2. Anglani F, D'Angelo A, Bertizzolo LM, Tosetto E, Ceol M, Cremasco D, Bonfante L, Addis MA, Del Prete D. Nephrolithiasis, kidney failure and bone disorders in Dent disease patients with and without CLCN5 mutations. *SpringerPlus*, December 2015 4:492. First online 15 September 2015. 10.1186/s40064-015-1294-y. <http://link.springer.com/article/10.1186/s40064-015-1294-y/fulltext.html>
3. Runolfsson HL, Palsson R, Agustsdottir IM, Indridason OS, Edvardsson VO. Kidney Disease in Adenine Phosphoribosyltransferase Deficiency. Accepted for publication in *American Journal of Kidney Disease*. 2015.
4. Pagon RA, Adam MP, Ardinger HH, et al., editors. Primary Hyperoxaluria Type 3. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK316514/>. 2015. Sep 24.
5. Edvardsson VO, Palsson R, Sahota A. Adenine Phosphoribosyltransferase Deficiency. 2012 Aug 30 [Updated 2015 Jun 18]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK100238/>
6. Sigurjonsdottir VK, Runolfsson HL, Indridason OS, Palsson R, and Edvardsson VO. Impact of nephrolithiasis on kidney function. *BMC Nephrology*. 2015. August; 16:149. DOI: 10.1186/s12882-015-0126-1. URL: <http://www.biomedcentral.com/1471-2369/16/149>.
7. Oddsson A, Sulem P, Helgason H, Edvardsson VO, Thorleifsson G, Sveinbjörnsson G, Haraldsdottir E, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Masson G, Holm H, Gudbjartsson DF, Thorsteinsdottir U, Indridason OS, Palsson R, & Stefansson K. Common and rare variants associated with kidney stones and biochemical traits. *Nature Communications* DOI: 10.1038/ncomms8975. Published 14 Aug 2015.
8. Lee MH, Sahota A, Ward MD, Goldfarb DS. Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases. *Curr Rheumatol Rep*. 2015. May; 17(5):510. PubMed PMID: 25874348.
9. Lieske JC, Goldfarb DS, Milliner DS. The link between bariatric surgery and kidney stones, "Beyond the Abstract." Published 14 May 2015. http://urotoday.com/index.php?Itemid=856&option=com_content&view=article&catid=1143&id=80680
10. Amin R, Eid L, Edvardsson VO, Fairbanks L, Moudgil A. An unusual cause of pink diapers in an infant: Questions. *Pediatr Nephrol*. 2015 Apr 1. PubMed PMID: 25823987.
11. Lieske JC, Mehta RA, Milliner DS, Rule AD, Bergstralh EJ, Sarr MG. Kidney stones are common after bariatric surgery. *Kidney Int*. 2015. Apr; 87(4): 839-45. Epub. 2014 Oct 29. PMID: 25354237. PMID: 4382441. DOI:10.1038/ki.2014.352.
12. Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC. Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. *Kidney Int*. 2015 Mar; 87(3): 623-31. Epub. 2014 Sep 17. PMID: 25229337. PMID: 4344931. DOI: 10.1038/ki.2014.298.
13. Carrasco A, Granberg CF, Gettman MT, Milliner DS, Krambeck AE. Surgical management of stone disease in patient with primary hyperoxaluria. In press, *Journal of Urology*. 2015. Mar; 85(3): 522-6. PubMed PMID: 25733260.
14. Berini SE, Tracy JA, Engelstad JK, Milliner DS, Lorenz EC, Dyck PJ. Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. *Muscle & Nerve* Epub 2015 Mar; 51(3): 449-54. PubMed PMID: 25363903; NIHMSID: NIHMS639791.
15. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. *J Am Soc Nephrol*. Epub. 2015. Feb 2. PubMed PMID: 25644115.
16. Sahota A, Parihar JS, Yang M, Capaccione K, Yang M, Noll K, Gordon D, Reimer D, Yang I, Buckley BT, Polunas M, Reuhl KR, Lewis MR, Ward MD, Goldfarb DS, Tischfield JA. Novel cystine ester mimics for the

- treatment of cystinuria-induced urolithiasis in a knockout mouse model. *Urology*. 2014. Nov; 84(5): 1249- E9-15. PubMed PMID: 25443947.
17. Zaidan M, Palsson R, Merieau E, Cornec-Le Gall E, Garstka A, Maggiore U, Deteix P, Battista M, Gagné ER, Ceballos-Picot I, Duong Van Huyen JP, Legendre C, Daudon M, Edvardsson VO, Knebelmann B. Recurrent 2,8-dihydroxyadenine nephropathy: a rare but preventable cause of renal allograft failure. *Am J Transplant*. 2014 Nov; 14(11):2623-32. PubMed PMID: 25307253.
 18. Tang X, Voskobojev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. *Am J Nephrol*. 2014; 39(5):376-82. PubMed PMID: 24776840.
 19. Rodgers A, Gauvin D, Edeh S, Allie-Hamdulay S, Jackson G, Lieske JC. Sulfate but not thiosulfate reduces calculated and measured urinary ionized calcium and supersaturation: implications for the treatment of calcium renal stones. *PLoS One*. 2014; 9(7):e103602. PMID:4111609
 20. Lieske JC, Turner ST, Edeh SN, Smith JA, Kardia SL. Heritability of urinary traits that contribute to nephrolithiasis. *Clin J Am Soc Nephrol*. 2014; 9:943-50. PMID:4011445.
 21. Tang X, Lieske JC. Acute and chronic kidney injury in nephrolithiasis. *Curr Opin Nephrol Hypertens*. 2014; 23:385-90. PMID: 4096690.
 22. Wang X, Krambeck AE, Williams JC Jr, Tang X, Rule AD, Zhao F, Bergstralh E, Haskic Z, Edeh S, Holmes DR 3rd, Hernandez LP, Lieske JC. Distinguishing characteristics of idiopathic calcium oxalate kidney stone formers with low amounts of Randall's plaque. *Clin J Am Soc Nephrol*. 2014; 9:1757-63. PMID: 4186508.
 23. Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. *Am J Transplant*. 2014. June; 14(6):1433-8. Epub 2014 May 02. PubMed PMID: 24797341.
 24. Lieske JC. New insights regarding the interrelationship of obesity, diet, physical activity, and kidney stones. *J Am Soc Nephrol*. 2014. 25: 211-212. PMID:PMC3904517
 25. Modersitzki F, Pizzi L, Grasso M, Goldfarb DS. Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers. *Urolithiasis*. 2014. Feb; 42(1): 53-60. PubMed PMID: 24253538.
 26. Nasr SH, Milliner DS, Wooldridge TD, Sethi S. Triamterence crystalline nephropathy. *Am J Kidney Dis*. 2014 Jan; 63(1):148-52 Epub 2013 Aug 16.
 27. Sumorok N, Goldfarb DS. Update on cystinuria. *Curr Opin Nephrol Hypertens* 2013; 22: 427-431.
 28. Lorenz EC, Michet CJ, Milliner DS, Lieske JC. Update on oxalate crystal disease. *Curr Rheumatol Rep* 2013; 15: 340. PMID:PMC3710657
 29. Worcester E, Evan A, Coe F, Lingeman J, Krambeck A, Sommers A, Philips C, Milliner D. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type 1. *Am J Physiol Renal Physiol*. 2013 Oct 2. PMID:PMC3882369.
 30. Edvardsson VO, Indridason OS, Haraldsson G, Kjartansson O, Palsson R. Temporal trends in the incidence of kidney stone disease in Iceland: Results of a nationwide study. *Kidney Int*. 2013. Jan;83(1):146-52. PMID: 22992468. PMC – Journal In Process
 31. Lee HJ, Jeong SJ, Park MN, Linnes M, Han HJ, Kim JH, Lieske JC, Kim SH. Gallotannin suppresses calcium oxalate crystal binding and oxalate- induced oxidative stress in renal epithelial cells. *Biol Pharm Bull*. 2012; 35(4):539-44. PMID:22466558. PMC – Journal in Process
 32. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. *Biochim Biophys Acta* 2012; 1822: 1544-1552. PMID: 22771891 PMID:PMC3418427.
 33. Pang R, Linnes MP, O'Connor HM, Li X, Bergstralh E, Lieske JC. Controlled Metabolic Diet Reduces Calcium Oxalate Supersaturation but Not Oxalate Excretion After Bariatric Surgery. *Urology*. 2012 May 01. PMID:PMC34118476.
 34. Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS. Primary hyperoxaluria type III gene HOGA1 (formerly DHAPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. *Clin J Am Soc Nephrol*. 2011 Sep; 6(9):2289-95. PMID:PMC3358997.
 35. Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschenes G, Unwin R, Milliner D. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. *Nephrol Dial Transplant*. 2011 Nov; 26(11):3609-15. PMID: 21460356. PMC – Journal In Process.

36. Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD. Crystal growth inhibitors for the prevention of l-cystine kidney stones through molecular design. *Science* 330:337, 2010. PMID: 20947757. doi: 10.1126/science.1191968.
37. Nasr SH, Sethi S, Cornell LD, Milliner DS, Boelkins M, Broviac J, Fidler ME. Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure. *Nephrol Dial Transplant*. 2010 Jun; 25(6):1909-15. PMID:20064951. PMC – Journal in Process
38. Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y. Mutations in DHAPSL are responsible for primary hyperoxaluria type III. *Am J Hum Genet*. 2010 Sep 10; 87(3):392-9. PMID:PMC2933339.
39. Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS, IPHR Investigators. Transplantation outcomes in primary hyperoxaluria. *Am J Transplant*. 2010 Nov; 10(11):2493-501. Epub 2010 Sep 17. PMID:PMC2965313.
40. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, Milliner DS. Cardiac abnormalities in primary hyperoxaluria. *Circ J*. 2010 Nov; 74(11):2403-9. Epub 2010 Sep 29. PMC – Journal in Process.
41. Mookadam F, El Kheir M, Alharthi M, Mustafa S, Kazmier FJ, McBain R, Mookadam M, Tajik JA, Milliner DS. Vascular involvement in primary hyperoxalosis: an evidence based systematic overview over a fifty year span. *Int J Nephrol Urol*. 2010; 2(3):390-496.